RUA Life Sciences Plc (RUA) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Mar 25

NET PROFIT(Q) At GBP -0.63 MM has Fallen at -46.51%
RAW MATERIAL COST(Y) Grown by 5.92% (YoY)

With ROE of 0.01%, it has a expensive valuation with a 0.98 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

GBP 7 Million (Micro Cap)

P/E

7.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.43

Return on Equity

0.01%

Price to Book

1.02

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.63%

6 Months

2.13%

1 Year

11.11%

2 Years

2.13%

3 Years

-63.64%

4 Years

-91.72%

5 Years

-92.84%

RUA Life Sciences Plc for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

35.81%

EBIT Growth (5y)

-0.61%

EBIT to Interest (avg)

-1.93

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.33

Tax Ratio

1.10%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

0.00%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.98

EV to EBIT

-3.98

EV to EBITDA

-3.98

EV to Capital Employed

0.96

EV to Sales

0.97

PEG Ratio

0.07

Dividend Yield

ROCE (Latest)

-23.89%

ROE (Latest)

0.01%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by RUA Life Sciences Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is 37.50% vs 6.67% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is 4.76% vs -40.00% in Mar 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.20",
          "val2": "1.60",
          "chgp": "37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-2.10",
          "chgp": "4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-2.10",
          "chgp": "4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,096.80%",
          "val2": "-1,494.80%",
          "chgp": "39.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Mar'23

Mar'23

Mar'22

Change(%)

Net Sales

2.20

1.60

37.50%

Operating Profit (PBDIT) excl Other Income

-2.00

-2.10

4.76%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.00

-2.10

4.76%

Operating Profit Margin (Excl OI)

-1,096.80%

-1,494.80%

39.80%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2023 is 37.50% vs 6.67% in Mar 2022

Consolidated Net Profit

YoY Growth in year ended Mar 2023 is 4.76% vs -40.00% in Mar 2022

All Annual Results

Company CV

About RUA Life Sciences Plc

RUA Life Sciences Plc

Pharmaceuticals & Biotechnology

RUA Life Sciences PLC, formerly AorTech International plc, is a biomaterials and medical device intellectual property (IP) company. The Company is focused on the commercialization of its biomedical polymer technology, components and medical devices. The Company has developed biostable, implantable polymers, including Elast-Eon and ECSil, which are long-term implantable co-polymers. Its Elast-Eon technology is available in a range of mechanical properties (Elastomers to rigid polymers), 70 Shore A to 80 Shore D. Its ECSil technology is available in a range of mechanical properties, but extends the softer materials to 70 Shore A. The Company has developed Elast-Eon and Reaction Injection Molding (RIM) technology for use in high-precision medical device components. Its polymers are developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices.

Company Coordinates

Company Details

2 Drummond Crescent, Irvine , AYRSHIRE None : KA11 5AN

Tel: 44 1294 317073

https://www.aortech.net/

Registrar Details